OneSource Specialty Pharma Ltd

- The company raised about INR 801 crores (~$100 million) recently, using half of it to retire high-cost and guarantee-backed debt. - They anticipate significant cash generation and customer participation to support the $100 million planned capex over the next 2-4 years. - The company aims to fund capex primarily from internal accruals and customer participation (reservation capacity fees), thus minimizing the need to borrow. - Current debt to EBITDA ratio is healthy, with plans to be debt-free by the end of FY 2027. - No explicit mention of any immediate plans for new fundraising through debt or equity beyond the recent capital raise. - The focus is on efficient use of internal cash flows along with partner risk-sharing for future investments.

- OneSource Specialty Pharma plans to invest about $100 million in capex over the next 2 to 4 years. - A significant part of this capex will be towards expanding drug-device combination (DDC) capacities. - Additional investments will be made to add new capabilities in the injectable space. - The company is proactively expanding capacities to meet growing customer demand, especially in the GLP-1 segment, increasing capacity from 40 million to 220 million units over 3 to 4 years. - Some customers participate in the capex program, contributing to capacity reservation fees, sharing risk with OneSource. - The capex will be primarily funded from internal accruals and proceeds from a recent capital raise. - The company sees the expansion as essential for capitalizing on future opportunities and increasing revenue up to $400 million within 3-4 years.

- OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue. - GLP-1 cartridge capacity to increase 5x from 40 million to 220 million units by 2028. - Expansion driven by new product approvals and increasing demand in emerging markets like Brazil, India, and China. - Commercial sales (CSA) expected to grow from 20% to 80% of volumes by FY27. - Anticipates a steady-state, predictable commercial business beyond FY27 with more than 40% EBITDA margins. - Strong customer base with 20 GLP-1 customers and 60+ overall, supporting expanded capacity. - New capacities to come online gradually from FY26 onwards, with expected revenue ramp-up in H2 FY26. - Biologics business to commercialize more substantially after 3-4 years, offering long-term growth beyond the current guidance period.

- OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%. - EBITDA margins are expected to be very strong, targeted at around 40%. - EPS for the recent quarter stood at INR 7.8 (fully diluted). - Return on capital employed (ROCE) is in the mid-30% range and trending positively. - Management is confident in achieving commitments on growth, EBITDA, and ROCE over 3-4 years. - The company expects steady quarter-on-quarter business growth beyond FY27. - Cash flow generation is projected to be significant with capex funded largely from internal accruals, supporting further expansion without borrowing. - The EBITDA margin range for FY26 is guided to be consistent with the current quarter (~36%), with some quarterly fluctuations expected.

- OneSource has customers providing reservation fees to block dedicated capacity. - Customers have given forecasts ranging from 24 to 36 months, with 12 to 18 months being binding forecasts, equivalent to "take or pay" arrangements. - The company proactively expands capacity to support customer demand. - Current capacity of 40 million units is insufficient; plans are to increase capacity 5x to approximately 220 million units over 3 to 4 years. - Strong demand and robust forecasts from 20 leading generic players, many of whom have significant market share. - Capacity expansion is backed by customer participation through reservation fees, mitigating investment risks. - The expected ramp-up aligns with markets coming off patent and growing demand for GLP-1 products globally.